96 Kensington High Street
28 articles with MiNA Therapeutics
10/2/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced the appointment of Peter Bains as Chief Business Officer, effective September 22, 2020.
The financing will be used by MiNA to advance the company’s pipeline of proprietary, first-in-class, small activating RNA therapeutics.
MiNA Therapeutics Secures £23 Million Series A Financing to Advance First-in-Class Activating RNA-Based Therapeutics
Funding, led by aMoon, will advance the clinical development of MiNA’s new class of RNA therapeutics for cancer treatment, and further expand its R&D pipeline in additional disease areas
MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL‑CEBPA in Combination with Sorafenib in Liver Cancer at 2020 ASCO Annual Meeting
Observed clinical activity, including durable and complete tumour responses, suggests that MTL‑CEBPA may increase the effectiveness of sorafenib standard of care
5/28/2020Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
MiNA Therapeutics Announces Publication of Phase I Liver Cancer Data in Clinical Cancer Research and Provides Update on Clinical Development and Drug Discovery Programs
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced the publication of data from its Phase I liver cancer trial, OUTREACH, in Clinical Cancer Research.
3/5/2020Life sciences companies from across the globe provide updates on their businesses and pipelines.
MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL‑CEBPA in Combination with anti-PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumours
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced the initiation and first patient treated in TIMEPOINT, a global Phase 1/1b clinical study of MTL-CEBPA in combination with anti-PD1 checkpoint inhibitor pembrolizumab in patients with advanced solid tumours.
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced the initiation of a research collaboration with AstraZeneca to evaluate small activating RNA molecules in metabolic diseases.
MiNA said the collaboration will combine its “expertise in the discovery and development of saRNA therapeutics” with AstraZeneca’s experience in “identifying and bringing breakthrough treatments to patients with metabolic diseases.”
MiNA Therapeutics Presents Clinical and Pre-Clinical Data at ESMO Supporting MTL-CEBPA as Immunological Combination Treatment
Final results from Phase 1 study of MTL-CEBPA in advanced liver cancer patients demonstrate clinical activity and attractive safety profile
MiNA Therapeutics Presents Pre-Clinical Data Supporting Combination of MTL-CEBPA with Sorafenib and Other Cancer Treatments at AACR
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced pre-clinical data supporting the immunological effects of MTL-CEBPA and its benefits in combination with other anti-cancer interventions including sorafenib, anti-PD1 checkpoint inhibition and radiofrequency ablation.
The American Association for Cancer Research (AACR) Annual Meeting is taking place in Atlanta. Here’s a look at just a few stories coming out of the meeting.
MiNA Therapeutics Announces Enrolment of Patients in Expansion of Phase Ib Trial Evaluating MTL-CEBPA in Combination with Sorafenib
MiNA Therapeutics, announced enrolment of the first patients treated with MTL-CEBPA in combination with Sorafenib in OUTREACH, the multi-centre Phase 1b clinical trial in patients with advanced liver cancer.
MiNA Therapeutics remains on track with current development plans for small activating RNA medicines including clinical development of MTL-CEBPA drug candidate
MiNA Therapeutics Announces Findings From MTL-CEBPA Clinical Trial in Patients with Advanced Liver Cancer at International Liver Cancer Association Conference
Oral presentation by trial’s Chief Investigator describes complete tumour responses reported in patients off-study when subsequently administered standard of care
MiNA Therapeutics Presents Initial Results from First-in-Human MTL-CEBPA Study in Advanced Liver Cancer Patients
MiNA Therapeuticstoday announced preliminary results from its ongoing Phase I study of small activating RNA (saRNA) candidate MTL-CEBPA in advanced liver cancer.
MiNA Therapeutics Announces Publication of Pre-Clinical Data Supporting Therapeutic Potential of Clinical Candidate MTL-CEBPA in Liver Cancer and Liver Disease
Data published in oncogene demonstrate improvement of liver function and increased survival in multiple disease models
11/27/2017Boehringer has made a big push into RNA this month.